ADiTx Therapeutics, Inc. Uncategorized Contracts & Agreements

At The Market Offering Agreement dated December 20, 2022 between Aditxt, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on December 20, 2022)

Revenue Sharing Agreement by and among Aditxt, Inc., Cellvera Global Holdings LLC and Cellvera Asia Limited dated as of March 31, 2022 (Filed With SEC on May 16, 2022)

First Amendment to Transaction Agreement dated November 30, 2021, by and between the Company and AiPharma Global Holdings LLC (Filed With SEC on March 31, 2022)

Second Amendment to Transaction Agreement dated December 7, 2021, by and between the Company and AiPharma Global Holdings LLC (Filed With SEC on March 31, 2022)

Third Amendment to Transaction Agreement dated December 17, 2021, by and between the Company and AiPharma Global Holdings LLC (Filed With SEC on March 31, 2022)

Fourth Amendment to Transaction Agreement dated December 22,2021, by and between the Company and AiPharma Global Holdings LLC (Filed With SEC on March 31, 2022)

Floating Charge (Filed With SEC on November 15, 2021)

Transaction Agreement, dated as of October 4, 2021 by and between the company and AiPharma Global Holdings LLC (Filed With SEC on November 15, 2021)

Description of Securities Registered Under Section 12 of the Exchange Act (Filed With SEC on March 25, 2021)

Amendment Agreement, dated August 19, 2020 (Filed With SEC on August 20, 2020)

Amendment Agreement, dated July 1, 2020, by and between the Company and Loma Linda University (Filed With SEC on August 13, 2020)

Patent Licensing Agreement, dated February 3, 2020 (Filed With SEC on May 14, 2020)